Showing results (1-10 of 102) with videos related to
Sort By:
Pageof 11
Acta Neurologica Scandinavica|May 25, 2002
Olanzapine in Huntington's diseaseD Paleacu, M Anca, N GiladiNeuroepidemiology|December 18, 2001
Cross-sectional study of the prevalence of Parkinson's disease in the Kibbutz movement in IsraelM Anca, D Paleacu, H Shabtai, et al.Journal of Neurology|August 24, 2001
The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot studyN Giladi, T Gurevich, H Shabtai, et al.Clinical Neuropharmacology|December 17, 2004
Tetrabenazine treatment in movement disordersD Paleacu, N Giladi, O Moore, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|May 16, 2000
Risk factors for dementia, depression and psychosis in long-standing Parkinson's diseaseN Giladi, T A Treves, D Paleacu, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|March 23, 2001
Freezing of gait in patients with advanced Parkinson's diseaseN Giladi, T A Treves, E S Simon, et al.Parkinsonism & Related Disorders|June 1, 2002
Quality of sexual life in Parkinson's diseaseO Moore, T Gurevich, A D Korczyn, et al.Acta Neurologica Scandinavica|November 18, 2003
Rivastigmine (Exelon) for dementia in patients with Parkinson's diseaseN Giladi, H Shabtai, T Gurevich, et al.Journal of the Neurological Sciences|February 7, 1998
The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected siteN GiladiInternational Journal of Geriatric Psychiatry|September 20, 2007
Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled studyD Paleacu, Y Barak, I Mirecky, et al.Pageof 11